Peritoneal Carcinomatosis: Cytoreductive Surgery and HIPEC–-Overview and Basics

REFERENCES

• Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221(1):29–42.
   PubMed Web of Science ®Google Scholar
• Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, Garbit F, Grandclément E, Vignal J, Gilly FN. Intraperitoneal chemohyperhermia with mytomycin C for digestive tract patients with peritoneal carcinomatosis. Cancer 2000;88(11):2512–2519.
   PubMed Web of Science ®Google Scholar
• Gilly FN, Beaujard A, Glehen O, Grandclement E, Caillot JL, Francois Y, Sadeghi-Looyeh B, Gueugniaud PY, Garbit F, Benoit M, Bienvenu J, Vignal J. Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I-II study. Anticancer Res 1999;19(3B):2317–2321.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999;85(3):529–534.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43(Suppl):S15–S25.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In Peritoneal Carcinomatosis: Principles of Management, PH Sugarbaker (ed). Boston: Kluwer, 1996, 79–100.
   Google Scholar
• Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88(2):358–363.
   PubMed Web of Science ®Google Scholar
• Baron MA. Structure of the intestinal peritoneum in man. Am J Anat 1941;69:439–497.
   Google Scholar
• Sugarbaker PH. Peritoneum as the first line of defense in carcinomatosis. J Surg Oncol 2007;95:93–96.
   PubMed Web of Science ®Google Scholar
• Konigsrainer I, Zieker D, Beckert S, von Weyhern C, Löb S, Falch C, Brücher BLDM, Konigsrainer A, Glatzle J. Influence of local peritonectomy on recurrence in colorectal cancer: an experimental study in a standardized rat model. Cell Physiol Biochem 2009;23:371–378.
   PubMedGoogle Scholar
• Stelin G, Rippe B. A phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD. Kidney Int 1990;38:465–472.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Schellinx ME, Chang D, Koslowe P, von Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996;5:585–591.
   Google Scholar
• Yonemura Y, Bandou E, Kawamura T, Endou Y, Sasaki T. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol 2006;32:602–606.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Moreno S, Ortega-Perez G, Gonzalez-Bayon L. Indications and patient selection for cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Surg Onc 2009;100:287–292.
   PubMed Web of Science ®Google Scholar
• Rufián S, Muñoz-Casares FC, Briceño J, Diaz CJ, Rubio MJ, Ortega R, Ciria R, Morillo M, Aranda E, Muntane J, Pera C. Radical surgery–peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 2006;94:316–324.
   PubMed Web of Science ®Google Scholar
• Brücher BLDM, Königsrainer A. Peritonealcarcinose. CHAZ 2010;11(1):17–31.
   Google Scholar
• Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer 1989;63:364–367.
   PubMed Web of Science ®Google Scholar
• Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dube P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28(1):63–68.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. New standard of care for appendiceal epithelial malignancies and pseudomyxoma peritonei syndrome. Lancet Oncol 2006;7:69–76.
   PubMed Web of Science ®Google Scholar
• Konigsrainer I, Beckert S, Lehmann T, Ladurner R, Brücher BLDM, Konigsrainer A. Peritoneal carcinomatosis. Chirurg 2011;82(4):375–380.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996;15:49–58.
   Web of Science ®Google Scholar
• Verwaal VJ, Van Tinteren H, Van Ruth S, Zoetmulder FAN. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004;91:739–746.
   PubMed Web of Science ®Google Scholar
• Gilly FN, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, Bienvenu J, Burgard G, Guibert B, Banssillon V, Braillon G. Regional chemotherapy and intraoperative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994;41:124–129.
   PubMed Web of Science ®Google Scholar
• Kajitani T (Japanese Research Society for Gastric Cancer). The general rules for the gastric cancer study in surgery and pathology: part I. Clinical classification. Jpn J Surg 1981;11:127–139.
   PubMedGoogle Scholar
• Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, deBree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, LaMont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007;14:128–133.
   PubMed Web of Science ®Google Scholar
• Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Onc 2009;100:321–328.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am 2003;12:703–727.
   PubMedGoogle Scholar
• Vazquez V de L, Sugarbaker PH. Total anterior parietal peritonectomy. J Surg Oncol 2003;83:261–263.
   PubMed Web of Science ®Google Scholar
• Ozel L, Ozel MS, Toros AB, Kara M, Ozkan KS, Tellioglu G, Krand O, Koyuturk M, Berber I. Effect of early preoperative 5-fluorouracil on the integrity of colonic anastomoses in rats. World J Gastroenterol 2009 15(33):4156–4162.
   PubMed Web of Science ®Google Scholar
• Pelz JO, Doerfer J, Decker M, Dimmler A, Hohenberger W, Meyer T. Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model. Int J Colorectal Dis 2007;22:941–947.
   PubMed Web of Science ®Google Scholar
• Van der Speeten K, Stuart OA, Sugarbaker PH. Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy. Curr Drug Discov Technol 2009;6:72– 81.
   PubMedGoogle Scholar
• Dedrick RL, Myers CE, Bungay PM, De Vita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1–11.
   PubMedGoogle Scholar
• Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, Oliff L, Schlag P. Rationale for early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gastrointestinal cancer. Cancer Res 1990;50:5790–5794.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005;10:112–122.
   PubMed Web of Science ®Google Scholar
• Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia 2005;21:681–687.
   PubMed Web of Science ®Google Scholar
• Kusumoto T, Holden SA, Teicher BA. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Int J Hyperthermia 1995;11:575–586.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum (II) and mitomycin C. Cancer Res 1980;40:1165–1168.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 1998;41:147–154.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727–731.
   PubMed Web of Science ®Google Scholar
• Glehen O, Cotte E, Kusamura S, Deraco M, Baratti D, Passot G, Beaujard AC, Noel GF. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Onc 2008;98:242–246.
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a high morbid procedure? Ann Surg 2009;249:900–907.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Moreno S, Kusamura S, Baratti D, Deraco M. Postoperative residual disease evaluation in the locoreginal treatment of peritoneal surface malignancy. J Surg Onc 2008;98:237–241.
   PubMed Web of Science ®Google Scholar
• Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies. EJSO 2006;32:625–627.
   PubMed Web of Science ®Google Scholar
• Garofalo A, Valle M. Laparoscopy in the management of peritoneal carcinomatosis. Cancer J 2009;15(3):190–195.
   PubMed Web of Science ®Google Scholar
• Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Onc 2009;100:331–334.
   PubMed Web of Science ®Google Scholar
• Laterza B, Kusamura S, Baratti D, Olivia GD, Deraco M. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo 2009;23:187–190.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, Matsuda H, Mizumoto A, Matsuda T, Takao N, Ichinose M, Mizuno M, Miura M, Ikeda M, Ikeda S, Nakajima G, Nonemura J, Yuuba T, Masuda S, Kimura H, Matsuki N. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Onc 2009;100:311–316.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FAN. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004;91:739–746.
   PubMed Web of Science ®Google Scholar
• Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, Steves MA, Sugarbaker PH. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using coliseum technique. Ann Surg Oncol 1999;6:790–796.
   PubMed Web of Science ®Google Scholar
• Saxena A, Yan TD, Morris DL. A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg 2010;34:70–78.
   PubMed Web of Science ®Google Scholar
• Saxena A, Chua TC, Yan TD, Morris DL. Postoperative pancreatic fistula after cytoreductive surgery and perioperative intraperitoneal chemotherapy: incidence, risk factors, management and clinical sequelae. Ann Surg Oncol 2010;17(5):1302–1310.
   PubMed Web of Science ®Google Scholar
• Kerscher AG, Mallalieu J, Pitroff A, Kerscher F, Esquivel J. Morbidity and mortality of 109 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC) performed at a community hospital. Worl J Surg 2010;34:62–69.
   PubMed Web of Science ®Google Scholar
• Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, Trillet-Lenoir V, Sayag-Beaujard AC, Francois Y, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003;10(8):863–869.
   PubMed Web of Science ®Google Scholar
• Piso P, Slowik P, Popp F, Dahlke MH, Glockzin G, Schlitt HJ. Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2009;16:2188–2194.
   PubMed Web of Science ®Google Scholar
• Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, Francois Y, Vignal J, Gilly FN. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20–26.
   PubMed Web of Science ®Google Scholar
• Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993;113(6):631–636.
   PubMed Web of Science ®Google Scholar
• Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006;106(5):1144–1153.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004;85(2):61–67.
   PubMed Web of Science ®Google Scholar
• Franko J, Gusani NJ, Holtzman MP, Ahrendt SA, Jones HL, Zeh HJ, Bartlett DL. Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol 2008;15(11):3065–3072.
   PubMed Web of Science ®Google Scholar
• Moradi BN, Esquivel J. Learning curve in cytoreductive surgery and hyperthermic intraperiotneal chemotherapy. J Surg Onc 2009;100:293–296.
   PubMed Web of Science ®Google Scholar
• Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high volume tertiary cancer center. Ann Surg Oncol 2007;15(3):754–763.
   PubMed Web of Science ®Google Scholar
• Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dube P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28(1):63–68.
   PubMed Web of Science ®Google Scholar
• Capone E, Valle M, Proietti F, Federici O, Garofalo A, Petrosillo N. Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Onc 2007;96:507–513.
   PubMed Web of Science ®Google Scholar
• Ronett BM, Shmookler BM, Sugarbaker PH, Kurman RJ. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 1997;2:197–226.
   PubMedGoogle Scholar
• Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003;22:465–472.
   PubMedGoogle Scholar
• Yan TD, Zappa L, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. J Surg Oncol 2007;96:102–112.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2010;17:45–53.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Patient selection and treatment of peritoneal carcinomatosis from colorectal and appendiceal cancer. World J Surg 1995;19:235–240.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, Dalton RR, Eltinghausen SE, Jacquet P, Jelinek J, Koslowe P, Kurman RJ, Shmookler B, Stephens AD, Steves MA, Stuart OA, White S, Zahn CM, Zoetmulder FA. Pseudomyxoma peritonei. Adv Surg 1997;30:233–280.
   Google Scholar
• Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Lab Med 2006;130:1654–1661.
   PubMed Web of Science ®Google Scholar
• Deraco M, De Simone M, Rossi CR, Cavaliere F, Difilippo F, Scuderi S, Pilatti P, Kusamura S. An Italian multicentric phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma. J Exp Clin Cancer Res 2003 22(4 Suppl):41–45.
   PubMed Web of Science ®Google Scholar
• Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohammed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27(3):6237–6242.
   PubMedGoogle Scholar
• Tentes AA, Tirpsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, Avgidou K. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 2003;29:69–73.
   PubMed Web of Science ®Google Scholar
• Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2003;13:764–770.
   PubMed Web of Science ®Google Scholar
• Muñoz-Casares FC, Rufián S, Rubio MJ, Díaz CJ, Díaz R, Casado A, Arjona A, Muñoz-Villanueva MC, Muntané J. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol 2009;11(11):753–759.
   PubMed Web of Science ®Google Scholar
• Cotte E, Glehen O, Mohammed, Lamy F, Falandry C, Golfier F, Gilly FN. Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 2007;31:1813–1820.
   PubMed Web of Science ®Google Scholar
• Okajima K, Yamada S. Surgical treatment of far-advanced gastric cancer. Jpn J Cancer Clin 1986;32:1203–1209.
   PubMedGoogle Scholar
• Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000;58:96– 107.
   PubMed Web of Science ®Google Scholar
• Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer 1989;63:364–367.
   PubMed Web of Science ®Google Scholar
• Yamada S, Takeda T, Matsumoto K. Prognostic analysis of malignant pleural and peritoneal effusions. Cancer 1983;51:136–140.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Kawamura T, Bandou E, Takahasi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005;92:370–375.
   PubMed Web of Science ®Google Scholar
• Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, Francois Y, Vignal J, Gilly FN. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20–26.
   PubMed Web of Science ®Google Scholar
• Hall JJ, Loggie BW, Shen P, Beamer S, Douglas Case L, McQuellon R, Geisinger KR, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004;8:454–463.
   PubMed Web of Science ®Google Scholar
• Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol 2008 98(4):273–276.
   PubMed Web of Science ®Google Scholar
• Kuramoto M, Shimada S, Ikeshima S, Matsuo A, Yagi Y, Matsuda M, Yonemura Y, Baba H. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 2009;250(2):242–246.
   PubMed Web of Science ®Google Scholar
• Pfannenberg C, Konigsrainer I, Aschoff P, Öksüz M, Zieker D, Beckert S, Symons S, Nieselt K, Glatzle J, Brücher BLDM, Claussen CD, Konigsrainer A. 18F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2009;16(5):1295–1303.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FAN. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004;91:739–746.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426–2432.
   PubMed Web of Science ®Google Scholar
• Li PC, Chen LD, Zheng F, Li Y. Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: results of an experimental study. J Cancer Res Clin Oncol 2008;134:37–44.
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232–239.
   PubMed Web of Science ®Google Scholar
• Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009;15:167–170.
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinalis F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220–231.
   PubMed Web of Science ®Google Scholar
• Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomized trials unnecessary? Picking signal from the noise. Brit Med J 2007;334(7589):349–351.
   PubMed Web of Science ®Google Scholar
• Nissan A, Stojadinovic A, Garofalo A, Esquivel J, Piso P. Evidence-based medicine in the treatment of peritoneal carcinomatosis: past, present, future. J Surg Onc 2009;100:335–344.
   PubMed Web of Science ®Google Scholar
• Chua TC, Martin S, Cert G, Saxena A, Liauw W, Yan TD, Zhao J, Lok I, Cert G, Morris DL. Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program. Ann Surg 2010;251(2):323–329.
   PubMed Web of Science ®Google Scholar
• Wagner BJ, Löb S, Lindau D, Hörzer H, Gückel B, Klein G, Glatzle J, Rammensee HG, Brücher BLDM, Konigsrainer A. Simvastatin reduced tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin. Int J Oncol 2011;39(6):1593–1600.
   PubMed Web of Science ®Google Scholar